53 Recruiting Neuroendocrine Tumors Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Neuroendocrine Tumors
Top Recruiting Neuroendocrine Tumors Studies
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
📍 Rocky Mountain Cancer Center — Denver, Colorado
View Study & Checklist ➔Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
📍 Juravinski Cancer Centre — Hamilton, Ontario
View Study & Checklist ➔A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
📍 Holden Comprehensive Cancer Center at the University of Iowa — Iowa City, Iowa
View Study & Checklist ➔Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
📍 Banner Health d.b.a. Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Post-Authorization Long-Term Safety Study of LUTATHERA
📍 Banner MD Anderson Cancer Center — Phoenix, Arizona
View Study & Checklist ➔Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
📍 University of Alberta Hospital — Edmonton, Alberta
View Study & Checklist ➔Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
📍 Holden Comprehensive Cancer Center — Iowa City, Iowa
View Study & Checklist ➔Neuroendocrine Tumors - Patient Reported Outcomes
📍 University of Florida — Gainesville, Florida
View Study & Checklist ➔Personalized PRRT of Neuroendocrine Tumors
📍 CHU de Québec - Université Laval — Québec, Quebec
View Study & Checklist ➔Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
📍 Stanford Cancer Center — Palo Alto, California
View Study & Checklist ➔Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
📍 Providence Portland Cancer Institute - Franz Clinic — Portland, Oregon
View Study & Checklist ➔Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
📍 Princess Margaret Cancer Centre — Toronto, Ontario
View Study & Checklist ➔DOTATOC PET/CT for Imaging NET Patients
📍 BC Cancer — Vancouver, British Columbia
View Study & Checklist ➔Evaluation of Study Experiences of Neuroendocrine Tumor Patients
📍 Power Life Sciences — San Francisco, California
View Study & Checklist ➔Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
📍 Royal North Shore Hospital — Sydney, New South Wales
View Study & Checklist ➔Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
📍 University of California, San Francisco — San Francisco, California
View Study & Checklist ➔177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
📍 Holden Comprehensive Cancer Center at the University of Iowa — Iowa City, Iowa
View Study & Checklist ➔A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
📍 Cross Cancer Institute — Edmonton, Alberta
View Study & Checklist ➔A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
📍 Emory University — Atlanta, Georgia
View Study & Checklist ➔Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
📍 Clinical Research Institute at Methodist Health System — Dallas, Texas
View Study & Checklist ➔The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View Study & Checklist ➔68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
📍 University of Alberta — Edmonton, Alberta
View Study & Checklist ➔